SCHEMBL3634860

SCHEMBL3634860

BrCCCN(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.51
HDAC1 Q13547 2/20 0.51
HDAC2 Q92769 2/20 0.51
HDAC8 Q9BY41 2/20 0.51
NCOR2 Q9Y618 2/20 0.51
TDP1 Q9NUW8 1/20 0.46
OPRM1 P35372 2/20 0.45
CHRM2 P08172 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
CHRM1 P11229 1/20 0.45
DRD1 P21728 1/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
ADRA1A P35348 1/20 0.45
DRD3 P35462 1/20 0.45
SLC6A3 Q01959 1/20 0.45
KCNH2 Q12809 1/20 0.45
ALDH1A1 P00352 2/20 0.44
TSHR P16473 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18410710 0.95 HDAC3 (0.47) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL11795941 0.88 HDAC3 (0.56) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL4974601 0.88 HDAC3 (0.61) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL2240248 0.86 TDP1 (0.50) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL11673147 0.86 HDAC3 (0.62) HDAC3HDAC1HDAC2HDAC8NCOR2
Bromide SCHEMBL10680860 0.84 TDP1 (0.48) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL4081568 0.83 HTT (0.55) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL8828024 0.82 CHRM2 (0.67) OPRM1CHRM2HTR1AADRA2ACHRM1
SCHEMBL537951 0.81 TDP1 (0.50) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL19635145 0.81 SIGMAR1 (0.65) ALDH1A1TSHRMAOBACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098529-A1 KINESIN KIF18A INHIBITORS AND USE THEREOF SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2026-05-15 WO disclosed
CN-111592467-B Nilaparib intermediate, preparation method and application thereof, and synthetic method of nilapab 宁波人健化学制药有限公司 2022-12-13 CN disclosed
EP-3053944-B1 METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR SHINETSU CHEMICAL CO (JP) 2021-10-06 EP disclosed
CN-111592467-A Nilaparib intermediate, preparation method and application thereof, and synthesis method of nilapab 宁波人健化学制药有限公司 2020-08-28 CN disclosed
EP-3412700-B1 COMPOUNDS SHINETSU CHEMICAL CO (JP) 2020-05-20 EP disclosed
EP-2744762-B1 METHOD FOR PRODUCING COATED GLASS SURFACES AND GLASS CONTAINERS MADE THEREWITH FREIE UNIVERSITÄT BERLIN (DE) 2017-11-15 EP disclosed
US-20170275305-A1 METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR SHINETSU CHEMICAL CO (JP) 2017-09-28 US disclosed
US-20170275305-A1 METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR SHINETSU CHEMICAL CO (JP) 2017-09-28 US disclosed
US-9708350-B2 Method for producing polyalkylene glycol derivative having amino group at end, polymerization initiator for use in the same, and alcohol compound as raw material for the polymerization initiator SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-07-18 US disclosed
US-9708350-B2 Method for producing polyalkylene glycol derivative having amino group at end, polymerization initiator for use in the same, and alcohol compound as raw material for the polymerization initiator SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-07-18 US disclosed
US-20160159831-A1 METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-06-09 US disclosed
US-20100292214-A1 Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2010-11-18 US disclosed
EP-2155676-A2 COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS Commissariat à l'Energie Atomique (FR) 2010-02-24 EP disclosed
WO-2008146172-A2 COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2008-12-04 WO disclosed
EP-1997805-A1 Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans Commissariat à l'Energie Atomique (FR) 2008-12-03 EP disclosed
EP-1404691-B1 METHOD FOR PRODUCING PERACYLATED 1-O-GLYCOSIDES SCHERING AG (DE) 2005-03-09 EP disclosed
US-6831164-B2 Generation of peracylated 1-O-glycosides; obtain chemical intermediate, react with alkylating agent, heat and recover product SCHERING AKTIENGESELLSCHAFT (DE) 2004-12-14 US disclosed
EP-1404691-A2 METHOD FOR PRODUCING PERACYLATED 1-O-GLYCOSIDES SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-07 EP disclosed
US-20030069402-A1 Process for the production of peracylated 1-0-glycosides SCHERING AG (DE) 2003-04-10 US disclosed
WO-2003006474-A2 METHOD FOR PRODUCING PERACYLATED 1-O-GLYCOSIDES SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275305-A1 METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR ADH1A, ADH1C, AP3M1 HDAC3 4219/4885HDAC1 2819/4885HDAC2 3742/4885
US-20030069402-A1 Process for the production of peracylated 1-0-glycosides B3GNT2, UGT8, UGGT1 HDAC3 401/4885HDAC1 724/4885HDAC2 1185/4885
US-20160159831-A1 METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END KCNMA1, KCNMB1, KCNMB4 HDAC3 3694/4885HDAC1 2715/4885HDAC2 3944/4885
US-20100292214-A1 Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans ABCB11, TPP1, ABCB1 HDAC3 642/4885HDAC1 1060/4885HDAC2 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.